Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $87.28M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.39
• Revenue Growth: -70.31%
• EPS Growth: -11.68%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 93,004,600
• 10 Day Avg. Volume: 806,010
• 30 Day Avg. Volume: 1,053,181
• PEG Ratio: N/A
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 0.93
• Enterprise Value/Gross Profit: 11.35
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: $5.20
• Price Target Upside: 453.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Caribou Biosciences faces substantial financial hurdles, with no revenue and consistent cash flow issues, which severely impact its financial performance score. Despite a strong balance sheet characterized by low leverage, profitability remains a concern. Technical analysis suggests bearish trends, although there is some potential for upward movement. Valuation metrics are unfavorable, reflecting ongoing losses and lack of dividends, further impacting the overall score.

Positive Factors

Financial Performance

The company ended the period with $212.5 million in cash and equivalents, expected to fund upcoming developments.

Product Development

CRBU plans to share pivotal design and timeline based on FDA feedback for CB-010 in 2L LBCL, contingent on positive data.

Negative Factors

Clinical Risks

Risks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and failure to achieve favorable clinical results with other pipeline candidates.

Pipeline Reduction

The discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research does reduce the value from the pipeline.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. (CRBU) is a biotechnology company specializing in genome editing and therapeutic development. The company is at the forefront of advancing CRISPR-Cas9 technology to develop transformative therapies for patients with significant unmet medical needs. Caribou's core focus is on creating innovative and precise genetic engineering solutions aimed at revolutionizing the treatment of diseases, particularly in the field of oncology.

How the Company Makes Money

Caribou Biosciences generates revenue through a combination of licensing agreements, partnerships, and development collaborations. The company licenses its proprietary CRISPR-Cas9 technology to other biotech firms and research institutions, which allows them to generate upfront fees, milestone payments, and royalties based on the success of the licensed products. Additionally, Caribou engages in strategic partnerships and collaborations with pharmaceutical companies to co-develop novel therapies, sharing both the costs and potential profits of successful treatments. These collaborations often involve joint research efforts and clinical development programs, enhancing Caribou's ability to bring its therapies to market. Furthermore, any proprietary products developed by Caribou and successfully commercialized can also contribute to direct sales revenue.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences is facing significant financial challenges with no revenue in the latest period, negative profits, and consistent cash flow deficits. While the company's balance sheet shows a low debt-to-equity ratio, indicating prudent leverage management, it is not translating into profitability. The company needs to address its cash flow and profitability issues to improve its financial standing.

Income Statement

Caribou Biosciences has shown no revenue for the latest year, and its net income has been consistently negative, indicating ongoing financial challenges. The revenue growth rate has been volatile, with significant fluctuations year over year. Margins, such as EBIT and EBITDA, are negative, reflecting persistent operational inefficiencies.

Balance Sheet

The company has a strong equity base compared to its debt, resulting in a low debt-to-equity ratio. However, the negative return on equity indicates that the company is not generating profit from its equity. The equity ratio has been relatively stable, suggesting a solid capital structure despite ongoing losses.

Cash Flow

Caribou Biosciences has negative operating and free cash flows, highlighting cash management issues. The cash flow to net income ratios are not favorable, reflecting cash flow challenges. The company has been reliant on financing activities to cover cash flow deficits.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.99M	34.48M	13.85M	9.60M	12.36M
	Gross Profit
6.07M	-77.60M	10.21M	8.61M	-22.06M
	EBIT
-166.62M	-116.06M	-106.40M	-66.98M	-36.12M
	EBITDA
-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
	Net Income Common Stockholders
-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
209.54M	328.83M	317.04M	413.51M	15.95M
	Total Assets
313.31M	432.21M	373.76M	442.36M	36.05M
	Total Debt
26.49M	27.11M	27.75M	259.00K	1.58M
	Net Debt
10.19M	-24.05M	-30.59M	-240.16M	-14.38M
	Total Liabilities
60.36M	63.81M	72.89M	54.53M	59.48M
	Stockholders Equity
252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow		Free Cash Flow
-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
	Operating Cash Flow
-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
	Investing Cash Flow
86.61M	-68.18M	-93.25M	-176.40M	6.36M
	Financing Cash Flow
16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.94
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Positive. The current price of 0.94 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.88, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.13 is Neutral, neither overbought nor oversold. The STOCH value of 87.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
EDIT	51 Neutral	$124.73M	―	-140.82%	―	-48.37%	-44.70%
MGNX	50 Neutral	$99.68M	―	-60.25%	―	255.31%	-141.39%
VXRT	48 Neutral	$115.28M	―	-114.74%	―	433.43%	49.04%
CRBU	44 Neutral	$87.28M	―	-52.76%	―	-70.31%	-11.68%
ZURA	43 Neutral	$68.68M	―	-62.34%	―	―	86.65%
ELTX	30 Underperform	$93.42M	―	-744.59%	―	―	27.65%

Caribou Biosciences Corporate Events

Caribou Biosciences Advances CAR-T Therapy Trials

Caribou Biosciences announced the initiation of the GALLOP Phase 1 clinical trial for CB-010 in lupus patients and provided significant updates on its CAR-T cell therapy programs for hematologic malignancies. The company plans to present data from several Phase 1 trials and potentially begin a pivotal Phase 3 trial in 2025, contingent on positive results. These developments are expected to enhance Caribou’s position in the allogeneic CAR-T cell therapy market, offering broader patient access and quicker treatment availability.